DeepSeek has driven the widespread adoption of AI applications, with the market anticipating medical AI as the next emerging field. EVER FORTUNE AI stated that by lowering the cost of entry through the open language model, it will help promote the potential market for medical applications. The company plans to strengthen the multidimensional integration of its three main product areas this year and will also seek certifications for listings on major online platforms in Europe and the U.S. to expand its overseas reach.

The market also estimates that EVER FORTUNE AI is likely to distribute a cash dividend of NT$1 per share this year, with revenue expected to show strong double-digit growth. The company also highlighted that its new application developments are focused on brain neurology, cardiovascular diseases, and cancer, having already obtained 43 medical device licenses domestically and internationally, including 12 FDA approvals. This year, the team will continue to focus on acquiring certifications for new products, with an even greater emphasis on the horizontal integration of certified products and strengthening connections with international major players.

In overseas markets, EVER FORTUNE AI noted that its demo site in Vietnam has been completed, and the next steps will include team and physician training. In Europe and the U.S., electronic trading platforms specifically for medical AI software are becoming increasingly mature, and the company is working to introduce its products into relevant supply chains to further expand its overseas revenue.

Resource: 長佳智能:成本降有助醫療AI更普及；今年更重整合